Xcafal Tablet DT contains Cefpodoxime Proxetil 200mg, a third-generation cephalosporin antibiotic effective against a broad spectrum of bacterial infections. It is indicated for the treatment of respiratory tract infections, urinary tract infections, skin and soft tissue infections, otitis media, and uncomplicated gonorrhea caused by susceptible strains of bacteria. Cefpodoxime Proxetil works by inhibiting bacterial cell wall synthesis, leading to cell lysis and death. The dispersible tablet formulation allows for rapid disintegration in the oral cavity, facilitating ease of administration, particularly in pediatric and geriatric patients who may have difficulty swallowing conventional tablets. Xcafal Tablet DT demonstrates good oral bioavailability and achieves therapeutic concentrations in respiratory secretions, urinary tract, and other tissues. It is generally well tolerated; common adverse effects include gastrointestinal disturbances such as diarrhea, nausea, and abdominal pain. Hypersensitivity reactions may occur in patients with a history of penicillin or cephalosporin allergy. Dosage and duration of therapy should be guided by the severity of infection and renal function status. Xcafal Tablet DT should be used under medical supervision with adherence to prescribed dosing to minimize resistance development and ensure optimal clinical outcomes.